Loading
Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.
Approved 1978. Weekly cisplatin with radiation has been the backbone of curative cervical cancer treatment since five 1999 trials (the NCI alert), and remains so within KEYNOTE-A18 and INTERLACE. Nephrotoxicity, ototoxicity, neuropathy, and emesis limit it; carboplatin substitutes when kidneys or hearing are at risk.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Forms intrastrand DNA crosslinks (1,2-GpG) that block replication and transcription; radiosensitises by inhibiting repair of radiation-induced damage.
1.Enters the cell and loses chloride ligands to become reactive
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. HCPCS J9060. Generic; low unit cost.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: cisplatin. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Region | Year | Indication |
|---|---|---|
| US | 1978 | Testicular and ovarian cancer; bladder cancer 1993 |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Nausea and vomiting Without modern antiemetics; ~30% with NK1/5-HT3 prophylaxis | 90% | - |
| Nephrotoxicity (any grade) | 30% | - |
| Ototoxicity Dose-dependent, higher in children | 40% | - |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (cisplatin) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Adjuvant treatment for lung cancer is now chosen by genotype. A resected ALK-positive tumour is treated with two years of a tablet instead of four cycles of platinum, which is a different life as well as a different outcome.
Pembrolizumab with gemcitabine-cisplatin is an approved first-line option for advanced biliary tract cancer alongside durvalumab-based therapy.
Adding chemotherapy to osimertinib delays progression. Whether it extends life, and whether the same benefit could be had by giving the chemotherapy later to the patients who need it, is what the overall survival analysis and the registry watch on this roadmap are for.
Perioperative immunotherapy is now standard for resectable lung cancer without a targetable driver. The updated overall survival hazard ratio of 0.89, with a confidence interval crossing one, is the honest state of the evidence on whether it cures more people.
The strongest signal that neoadjuvant immunotherapy makes stage III lung cancer operable as well as more often curable. Twenty-four percentage points more patients reaching surgery is a result that only a neoadjuvant design can produce.
Durvalumab with gemcitabine-cisplatin is a first-line standard for advanced biliary tract cancer, with pembrolizumab (KEYNOTE-966) as the alternative.
Adjuvant immunotherapy entered lung cancer here, and with it the question that still divides practice: whether it is better given before the operation, after it, or on both sides.
The standard-of-care rows on the locoregionally advanced nasopharyngeal page follow this guideline.
Query for this drug: (TITLE:"Cisplatin" OR ABSTRACT:"Cisplatin" OR TITLE:"Platinol" OR ABSTRACT:"Platinol" OR TITLE:"generic" OR ABSTRACT:"generic") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cisplatin, not a curated reading list.
Shares A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors, A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer, A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors, A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer.
Shares Phase 3 trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma, A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L, JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara, Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC.
Shares A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)], A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors, Cosiporfin Sodium for Injection Photodynamic Therapy, Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors.
Shares Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study, A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer, Induction chemotherapy response as a guide to treatment optimisation in sinonasal undifferentiated carcinoma, Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours.
Shares Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours, Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases, Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial, A Phase II Trial of LM103 in Advanced Melanoma.
Shares Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors, A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation, Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC, FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease.
Shares A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02), A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer, A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer, CALLA.
Shares Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma, Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer, A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer, CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers.